SERVICES AGREEMENTServices Agreement • May 15th, 2013 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • Delaware
This Services Agreement (the “Agreement”) is entered into as of March 7, 2013 (the “Effective Date”) by and between SORRENTO THERAPEUTICS, INC., a Delaware corporation (“STI”) having an office at 6042 Cornerstone Court West, Suite B, San Diego, California 92121 (“STI”) and IGDRASOL, INC., a Delaware corporation (“IgDraSol”) having an office at 11100 Warner Avenue, Suite 266, Fountain Valley, California 92708. STI and IgDraSol may be referred to herein individually as a “Party” and collectively as the “Parties.”
OPTION AGREEMENT Dated as of March 7, 2013 by and between SORRENTO THERAPEUTICS, INC. and IGDRASOL, INC.Option Agreement • May 15th, 2013 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • Delaware
THIS OPTION AGREEMENT (this “Agreement”) is entered into as of March 7, 2013 by and between IgDraSol, Inc., a Delaware corporation having an office at 11100 Warner Avenue, Suite 266, Fountain Valley, California 92708 (“IgDraSol” or the “Company”) and Sorrento Therapeutics, Inc., a Delaware corporation having an office at 6042 Cornerstone Court West, Suite B, San Diego, California 92121 (“STI” or “Sorrento”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • May 15th, 2013 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • Delaware
THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made as of March 7, 2013 (“Effective Date”) between IgDraSol, Inc., a Delaware corporation having an office at 11100 Warner Avenue, Suite 266, Fountain Valley, California 92708 (“Seller”) and Sorrento Therapeutics, Inc., a Delaware corporation having an office at 6042 Cornerstone Court West, Suite B, San Diego, California 92121 (“Buyer”).
VOTING AGREEMENTVoting Agreement • May 15th, 2013 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • Delaware
THIS VOTING AGREEMENT (“Voting Agreement”) is entered into as of March 7, 2013, by and among SORRENTO THERAPEUTICS, INC., a Delaware corporation (“Sorrento”), IGDRASOL, INC., a Delaware corporation (the “IgDraSol”) and the stockholder signatories hereto (“Stockholder”).
ASSIGNMENT AGREEMENT by and between TIEN-LI LEE, M.D. AND JANE WU LEE, M.D., as individuals and SORRENTO THERAPEUTICS, INC., a Delaware (U.S.) corporationAssignment Agreement • May 15th, 2013 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • California
This Assignment Agreement (“Agreement”) is entered into and made effective as of this 7th day of January, 2013 (the “Effective Date”), by and between Tien-Li Lee and Jane Wu Lee as individuals (each individually, “Lee” or collectively, the “Lees”) each having an address at 270 Sebastian Drive, Millbrae, California 94030, and Sorrento Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Sorrento”) located at 6042 Cornerstone Ct., Suite B, San Diego, CA 92121, with respect to the facts set forth below.
